Helliwell T R, Atkinson M W, Cooke T G, Cooke L D, Stell P M
Department of Pathology, Otorhinolaryngology University of Liverpool, England.
Pathol Res Pract. 1989 Nov;185(5):755-9. doi: 10.1016/S0344-0338(89)80233-X.
The histopathology of 54 squamous carcinomas of the head and neck was evaluated by qualitative grading and morphometry in order to identify those features which predicted a good response to cisplatinum chemotherapy. The histopathology of 66 cases was correlated with tumour ploidy, determined by flow cytometry of paraffin-embedded material, since a separate study has shown that aneuploid carcinomas respond better to chemotherapy. The degree of differentiation was a poor predictor of ploidy, although diploid carcinomas did show more keratin and less nuclear pleomorphism than aneuploid carcinomas. The prominence of nucleoli in tumour cells and the surface area to volume (s/v) ratio of the tumour islands were the variables most strongly correlated with ploidy, with diploid carcinomas having prominent nucleoli and a low s/v ratio. A good response to chemotherapy was related partly to the architecture of the carcinoma (pushing border and low s/v ratio), and partly to the tumour cells (well differentiated) and the percentage of necrotic tumour. A lack of inflammatory reaction or desmoplasia was associated with a poor response. The results indicate that both subjective and objective histopathological criteria may be used to predict ploidy and the response to cisplatinum chemotherapy of squamous carcinoma of the head and neck. A combination of s/v ratio and the percentage of necrotic tumour can be used to identify a group of patients with a relatively good survival.
对54例头颈部鳞状细胞癌的组织病理学进行了定性分级和形态测量评估,以确定那些可预测对顺铂化疗有良好反应的特征。对66例病例的组织病理学与肿瘤倍体进行了相关性分析,肿瘤倍体通过对石蜡包埋材料进行流式细胞术测定,因为另一项研究表明非整倍体癌对化疗反应更好。分化程度对倍体的预测性较差,尽管二倍体癌的角化程度比非整倍体癌更高,核异型性更小。肿瘤细胞核仁的突出程度以及肿瘤岛的表面积与体积(s/v)比是与倍体相关性最强的变量,二倍体癌具有突出的核仁且s/v比低。对化疗的良好反应部分与癌的结构(推挤边界和低s/v比)有关,部分与肿瘤细胞(高分化)和坏死肿瘤的百分比有关。缺乏炎症反应或促纤维增生与反应较差相关。结果表明,主观和客观的组织病理学标准均可用于预测头颈部鳞状细胞癌的倍体和顺铂化疗反应。s/v比和坏死肿瘤百分比的组合可用于识别一组生存相对良好的患者。